ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback